Navigation Links
ViroPharma Incorporated Honored by the National Organization for Rare Disorders
Date:5/18/2009

ress releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Forward-Looking Statements

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide the Company's current expectations or forecasts of future events. Forward-looking statements in this press release include statements regarding ViroPharma's supplemental Biologics License Application for Cinryze for the treatment of acute attacks of HAE. Our actual results could differ materially from those results expressed in, or implied by, these forward-looking statements. The development and commercialization of pharmaceutical products is subject to risks and uncertainties. The data that were submitted to the U.S. Food and Drug Administration includes data from two separate studies including the pivotal Phase 3 study of Cinryze in acute HAE attacks and the ongoing open-label study of Cinryze for acute treatment of HAE, which includes partial data from an ongoing open label study. There can be no assurance that the complete data from the open label study will demonstrate that Cinryze successfully treats all types of acute hereditary angioedema (HAE) attacks and may not be predictive of the results of any future testing. The FDA may view the data regarding the use of Cinryze for acute treatment of HAE we have submitted as a supplemental BLA as insufficient or inconclusive, not accept our submission, request additional data, require additional clinical studies, delay any decision past the time frames anticipated by us, limit any approved indications, deny the approval of Cinryze for acute treatment of HAE or approve a co
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two Upcoming Healthcare Conferences
2. ViroPharma Provides 2008 Outlook
3. ViroPharma to Present at the BIO CEO & Investor Conference
4. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
5. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
6. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at Two Upcoming Healthcare Conferences
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
11. ViroPharma To Acquire Lev Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Sterlitech is proud to announce that it ... stable of products . These additional products increase ... membrane filters with surface charges. , “We ... our membrane process testing equipment, and correspondingly, a wider ... explains Sterlitech President Mark Spatz. “The addition of ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce that ... PTI Inspection Systems that will enable it to ... leak testing method development and validation programs using the ... part of this agreement, Whitehouse Labs has taken delivery ... developed and manufactured by PTI. The HVLD (high ...
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
Breaking Biology Technology:Sterlitech Corporation Enhances Its Selection of Flat Sheet Membrane Filters 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3
... SYDNEY, June 3 /PRNewswire-Asia/ -- ... that it had raised A$47 million through a placement ... strengthens the company,s balance sheet as Pharmaxis moves toward,the ... for cystic,fibrosis. , Pharmaxis will ...
... June 3 Speaker of the House Nancy Pelosi (D-CA) ... the unveiling of a statue of President Ronald Reagan today ... got her facts all wrong, misleading people again, this time ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , ...
... JERUSALEM, June 3 The Gamida Cell-Teva Joint Venture,announced today that ... two in Valencia, have joined the Excel study. , , ... - Hospital Clinic of Barcelona, Barcelona, Principal ... Universitario de Valencia, Valencia, Principal Investigator, Dr. Cristina ...
Cached Biology Technology:Pharmaxis Announces Placement of $47 Million and Share Purchase Plan 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 2Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma 3
(Date:8/29/2014)... release is available in German . ... players in the natural nitrogen cycle on Earth and ... bacteria were thought to depend on nitrite as their ... by Holger Daims, a microbiologist at the University of ... hydrogen as an alternative source of energy. The oxidation ...
(Date:8/29/2014)... them: modern materials that are light, flexible and highly ... or electronic paper. , Making such concepts affordable enough ... way of working with copper nanowires and a PVA ... success in the field of ultra-lightweight "aerogel monoliths" has ... silver nanowires. , By turning instead to copper, ...
(Date:8/28/2014)... of bacterial culprits that may drive inflammatory bowel diseases ... patients, own intestinal immune responses as a guide. , ... Cell . , Trillions of bacteria exist within ... in the development and progression of IBD. Yet it,s ... affect a person,s susceptibility to IBD and its potential ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Copper shines as flexible conductor 2Yale study identifies possible bacterial drivers of IBD 2
... Damselfish are killing head corals and adding stress ... poor condition from global climate change, coral diseases, hurricanes, ... favorite homestead, will take the pressure off the other ... online journal PLoS ONE . The small, ...
... miles of the nation,s infrastructure of water ... of its useful life, but the mostly ... attention because of this "invisibility," said Sunil ... and environmental engineering (CEE). http://www.cee.vt.edu/index.php?do=view&content=0&apps=2&level=2&id=17&pid=b024555fa7f439a27509de488a7b5749 ...
... most likely to occur on Sunday, in less than 6 ... wearing black and white bathing suits, a first of its ... analyzed statistics from shark attacks that occurred in Florida,s Volusia ... 1956 and 2008. They also spent a year observing people ...
Cached Biology News:Distressed damsels stress coral reefs 2Efforts underway at Virginia Tech to address deterioration of nation's water pipes 2Case study analyzes why, where and when of leading shark attack site 2Case study analyzes why, where and when of leading shark attack site 3
... template is designed to allow neomycin/kanamycin ... The loxP-PGK-gb2-neo-loxP template encodes the ... prokaryotic promoter (gb2) for expression of ... eukaryotic promoter (PGK) for expression of ...
... These precision 5mm diameter, 7 inch long ... glass for compatibility with ground joints, valves, and ... NMR spectrometers running from 300 to 500MHz. They ... an I.D. of 4.20 + 0.013-0.000mm. These NMR ...
... top performance with exquisite design. The 96 ... unparalleled temperature uniformity. The instrument has a ... spreadsheet or alternatively in a graphical mode. ... the push of a button and swings ...
... FastPlax Titer Kit is designed for determination of ... 46 days as in other methods. Classical determination ... of plaques, but the FastPlax Kit takes advantage ... gp64 glycoprotein on the cell surface as early ...
Biology Products: